US Stock Market Closed

Dashboard

Opiant Pharmaceuticals, Inc. (OPNT)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity
Analyst Opinion

B

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Opiant Pharmaceuticals, Inc. engages in the development of pharmaceutical solutions for common addictions and related disorders. It focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. Opiant Pharmaceuticals was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

CEO

Roger Crystal

Employees

21

Industry

-

Sector

-

Headquarters

Santa Monica

Exchange

NASDAQ

Summary Stats

Market Cap

54.3M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 2 analysts

High

$42.00

Average

$40.00

Low

$38.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q2 2022

Last Earnings

Missed by -$0.95

Actual

-$2.31 -69.9%

Consensus

-1.36

Report Date

Year Ago

0.31

Year Ago Change %

Down 845%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites